menu
The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%
The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%
Roots Analysis has done a detailed study on Microbial Contract Biomanufacturing Market, 2020-2030, covering key aspects of the industry and identifying potential future growth opportunities.

Roots Analysis has done a detailedstudy on Microbial ContractBiomanufacturing Market, 2020-2030, covering key aspects of the industry and identifyingpotential future growth opportunities.

 

To order this 320+ page report, which features 150+ figuresand 150+ tables, please visit this link

 

Key Market Insights

§ Over 115 companies, across the world, claim to offer avariety of product development, manufacturing and support services, for varioustypes of biologics that are manufactured / expressed in microbial systems

§ Majority of the players have the necessary infrastructure /capability to produce different biologics, primarily proteins, at all scalesusing bacterial / yeast expression vectors

§ The market features the presence of severalwell-established players across the globe; the US, the UK and Germany emergedas current hubs for production of biologics using microbial strains

§ Several service providers, involved in this domain, aresteadily expanding their capabilities in order to enhance their respectiveservice portfolio and maintain a competitive edge in the industry

§ The growth trend of outsourcing microbial manufacturingoperations is evident from the rise in recent partnership activity, as well asexpansion initiatives undertaken by CMOs to meet the growing demand for novelbiologics

§ Big pharma players have also made significant investmentsin this domain through establishment of new facilities, entering into strategiccollaborations and undertaking financial investments

§ Future growth of the market is likely to be driven byincreased adoption of novel biologics that are produced via microbial systems;we expect the service-based revenues to grow at a CAGR of over 8%

§ In the long term, the projected opportunity for contractbiomanufacturing is anticipated to be distributed across contract serviceproviders of different sizes, scales of manufacturing and key geographicalregions

 

For more information, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

 

Table of Contents

 

1.         PREFACE

1.1.       Scopeof the Report

1.2.       ResearchMethodology

1.3.       Chapter Outlines                     

 

2.         EXECUTIVESUMMARY

 

3.         INTRODUCTION

3.1        ChapterOverview

3.2.       Overviewof Biopharmaceuticals

 

3.3.       ExpressionSystems Used for Biopharmaceutical Production

3.3.1.    MicrobialExpression Systems

3.3.1.1. BacterialExpression Systems

3.3.1.2. FungalExpression Systems

3.3.1.3. YeastExpression Systems                   

3.3.2.    Mammalianversus Microbial Expression Systems

 

3.4.       MicrobialManufacturing Process

3.4.1.    CellBanking

3.4.2.    UpstreamProcessing

3.4.3.    Fermentation

3.4.4.    DownstreamProcessing

 

3.5.       Overviewof Contract Manufacturing

3.6.       Needfor Outsourcing Microbial Biomanufacturing Operations

3.7.       CommonlyOutsourced Microbial Biomanufacturing Operations

3.8.       Advantagesand Risks Associated with Outsourcing Microbial Biomanufacturing                                        Operations

3.9.       KeyConsiderations while Selecting a CMO Partner

3.10.     ConcludingRemarks     

 

 

4.         MARKETLANDSCAPE

4.1.       ChapterOverview

4.2.       MicrobialContract Biomanufacturing Market: Overall Market Landscape

4.2.1.    Analysisby Year of Establishment

4.2.2.    Analysisby Company Size

4.2.3.    Analysisby Location of Headquarters

4.2.4.    Analysisby Location of Manufacturing Facility

4.2.5.    Analysisby Scale of Operation

4.2.6.    Analysisby Type of Biologic

4.2.7.    Analysisby Type of Expression System Used

4.2.8.    Analysisby Type of Fermenter

4.2.9.    Analysisby Type of Service(s) Offered

4.2.10.  Analysisby Regulatory Accreditations / Certifications

4.3.       RegionalAnalysis

4.3.1.    Analysisby North America

4.3.2.    Analysisby Europe

4.3.3.    Analysisby Asia Pacific

4.3.4.    Analysisby Middle East and North Africa

 

5.         COMPANYCOMPETITIVENESS ANALYSIS

5.1.       ChapterOverview

5.2.       Assumptionsand Key Parameters

5.3.       Methodology

5.4.       CompetitivenessAnalysis

5.4.1.    CompetitivenessAnalysis: Companies in North America

5.4.2.    CompetitivenessAnalysis: Companies in Europe

5.4.3.    CompetitivenessAnalysis: Companies in Asia Pacific    

 

6.         COMPANYPROFILES

6.1.       ChapterOverview

6.2.       MicrobialContract Biomanufacturers based in North America

6.2.1.    AGCBiologics

6.2.1.1. CompanyOverview

6.2.1.2. ServicePortfolio

6.2.1.3. ManufacturingCapabilities and Facilities

6.2.1.4. RecentDevelopments and Future Outlook

           

6.2.2.    Aldevron

6.2.2.1. CompanyOverview

6.2.2.2. ServicePortfolio

6.2.2.3. ManufacturingCapabilities and Facilities

6.2.2.4. RecentDevelopments and Future Outlook

6.2.3.    BioVectra

6.2.3.1. CompanyOverview

6.2.3.2. ServicePortfolio

6.2.3.3. ManufacturingCapabilities and Facilities

6.2.3.4. RecentDevelopments and Future Outlook

 

6.2.4.    OlogyBioservices

6.2.4.1. CompanyOverview

6.2.4.2. ServicePortfolio

6.2.4.3. ManufacturingCapabilities and Facilities

6.2.4.4. RecentDevelopments and Future Outlook

 

6.3.       MicrobialContract Biomanufacturers Based in Europe

6.3.1.    Eurogentec

6.3.1.1. CompanyOverview

6.3.1.2. ServicePortfolio

6.3.1.3. ManufacturingCapabilities and Facilities

6.3.1.4. RecentDevelopments and Future Outlook

 

6.3.2.    NorthwayBiotechpharma

6.3.2.1. CompanyOverview

6.3.2.2. ServicePortfolio

6.3.2.3. ManufacturingCapabilities and Facilities

6.3.2.4. RecentDevelopments and Future Outlook

 

6.3.3.    PortonBiopharma

6.3.3.1. CompanyOverview

6.3.3.2. ServicePortfolio

6.3.3.3. ManufacturingCapabilities and Facilities

6.3.3.4. RecentDevelopments and Future Outlook

           

6.4.       MicrobialContract Biomanufacturers Based in Asia Pacific

6.4.1.    EirGenix

6.4.1.1. CompanyOverview

6.4.1.2. ServicePortfolio

6.4.1.3. ManufacturingCapabilities and Facilities

6.4.1.4. RecentDevelopments and Future Outlook

 

6.4.2.    Etinpro

6.4.2.1. CompanyOverview

6.4.2.2. ServicePortfolio

6.4.2.3. ManufacturingCapabilities and Facilities

6.4.2.4. RecentDevelopments and Future Outlook

 

6.4.3.    StelisBiopharma

6.4.3.1. CompanyOverview

6.4.3.2. ServicePortfolio

6.4.3.3. ManufacturingCapabilities and Facilities

6.4.3.4. RecentDevelopments and Future Outlook

 

7.         RECENTPARTNERSHIPS

7.1.       ChapterOverview

7.2.       PartnershipModels

7.3.       MicrobialContract Biomanufacturers: Recent Partnerships

7.3.1.    Analysisby Year of Partnerships

7.3.2.    Analysisby Type of Partnership Model

7.3.3.    Analysisby Scale of Operation

7.3.4.    Analysisby Type of Biologic

7.3.5.    Analysisby Focus Area

7.3.6.    Analysisby Target Therapeutic Area

 

7.3.7.    Analysisby Region

7.3.7.1. Country-WiseDistribution

7.3.7.2. Intercontinentaland Intracontinental Agreements

 

7.3.8.    MostActive Players: Analysis by Number of Partnerships

 

7.4.       MicrobialContract Biomanufacturers: Mergers and Acquisitions

7.4.1.    Analysisby Year of Merger / Acquisition

7.4.2.    Analysisby Type of Acquisition 

7.4.3.    RegionalAnalysis 

7.4.3.1. Continent-wise Distribution 

7.4.3.2. Country-wise Distribution 

7.4.3.3. Intercontinental and IntracontinentalDeals 

  

7.4.4.    MostActive Players: Analysis by Number of Acquisitions

7.4.5.    Analysisby Key Value Drivers  

7.4.5.1. Analysisby Year of Acquisition and Key Value Drivers

 

8.         RECENTEXPANSIONS

8.1.       ChapterOverview

8.2.       MicrobialContract Biomanufacturers: Recent Expansions

8.2.1.    Analysisby Year of Expansion

8.2.2.    Analysisby Type of Expansion

8.2.3.    Analysisby Scale of Operation

8.2.4.    Analysisby Type of Biologic

8.3.       GeographicalAnalysis

8.3.1.    Continent-wiseDistribution                   

 

9.         MICROBIALFERMENTATION TECHNOLOGY PLATFORMS

9.1.       ChapterOverview

9.2.       TechnologyPlatforms Commonly Used for Microbial Fermentation

9.3.       UpcomingPlatforms-General Technologies

 

10.        ATTRACTIVENESSCOMPETITION MATRIX

10.1.     ChapterOverview

10.2.     ACMatrix: An Overview

10.2.1.  StrongBusiness Segment

10.2.2.  AverageBusiness Segment

10.2.3.  WeakBusiness Segment

10.3.     AC Matrix:Analytical Methodology

10.4.     ACMatrix: Analyzing the Data for North America

10.5.     ACMatrix: Analyzing the Data for Europe

10.6.     ACMatrix: Analyzing the Data for Asia Pacific and Middle East

 

11.        MAKE VERSUSBUY DECISION MAKING FRAMEWORK

11.1.     ChapterOverview

11.2.     Assumptionsand Parameter Definitions

11.2.1.  Scenario1

11.2.2.  Scenario2

11.2.3.  Scenario3

11.2.4.  Scenario4

11.3.     ConcludingRemarks

                                                                       

12.        BIG PHARMAINITITATIVES IN MICROBIAL BIOMANUFACTURING

12.1.     ChapterOverview

12.2.     Listof Microbial Biopharmaceutical Manufacturing Initiatives of Big Pharma Players

12.2.1.  Analysisby Number of Initiatives

12.2.2.  Analysisby Year of Initiative

12.2.3.  Analysisby Company and Year of Initiative

12.2.4.  Analysisby Purpose of Initiative

12.2.5.  Analysis by Company and Purpose of Initiative

12.2.6.  Analysisby Type of Initiative

12.2.7.  Analysisby Scale of Operation

12.2.8.  Analysisby Type of Drug Molecule

12.2.9.  Analysisby Type of Microbial Expression System Used              

12.2.10. Geographical Analysis by Investment Made

 

12.3.     CompetitiveBenchmarking of Big Pharmaceutical Players

12.3.1. BigPharma Summary

 

13.        CASE STUDY:COMPARISON OF SMALL MOLECULE AND LARGE                           MOLECULEDRUGS / THERAPIES

13.1.     ChapterOverview

13.2.     SmallMolecule and Large Molecule Drugs / Therapies    

13.2.1. Comparisonof Key Characteristics

13.2.2. Comparisonof Microbial Manufacturing Process

13.2.2.1. Microbial Contract Manufacturers ProvidingServices for Small Molecules

13.2.3. Comparisonof Key Manufacturing-related Challenges

                                               

14.        MARKETSIZING AND OPPORTUNITY ANALYSIS

14.1.     ChapterOverview

14.2.     KeyAssumptions and Forecast Methodology

14.3.     OverallMicrobial Contract Biomanufacturing Market, 2020-2030

14.3.1.  MicrobialContract Biomanufacturing Market for APIs, 2020-2030

14.3.2.  MicrobialContract Biomanufacturing Market for FDFs, 2020-2030           

 

14.4.     Microbial ContractBiomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Biologic

14.5.     Microbial ContractBiomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of MicrobialExpression System Used

14.6.     Microbial Contract BiomanufacturingMarket, 2020, 2025 and 2030: Distribution by Scale of Operation

14.7.     MicrobialContract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of           End User

 

14.8.      Microbial ContractBiomanufacturing Market, 2020, 2025, 2030: Distribution by Key GeographicalRegions          

14.8.1.   Microbial ContractBiomanufacturing Market in North America, 2020-2030

14.8.1.1. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Proteins

14.8.1.2. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Enzymes

14.8.1.3. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Growth   Hormones

14.8.1.4. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Antibody-based Drugs

14.8.1.5. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Other Biologics

14.8.1.6. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Bacterial Cell-based Expression Systems

14.8.1.7. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Yeast Cell-based Expression Systems

14.8.1.8. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Other Microbial Cell-based Expression Systems

14.8.1.9. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Commercial Operations

14.8.1.10. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Preclinical / Clinical Operations

14.8.1.11. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Small Companies

14.8.1.12. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Mid-sized Companies

14.8.1.13. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Large / Very Large Companies

 

14.8.2.    Microbial Contract Biomanufacturing Market inEurope, 2020-2030

14.8.2.1. Microbial Contract Biomanufacturing Marketin Europe, 2020-2030: Share of Proteins

14.8.2.2. Microbial Contract Biomanufacturing Marketin Europe, 2020-2030: Share of Enzymes

14.8.2.3. Microbial Contract Biomanufacturing Marketin Europe, 2020-2030: Share of Growth Hormones

14.8.2.4. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Antibody-based Drugs

14.8.2.5. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Other Biologics

14.8.2.6. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Bacterial Cell-based Expression Systems

14.8.2.7. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Yeast Cell-based Expression Systems

14.8.2.8. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Other Microbial Cell-based Expression Systems

14.8.2.9. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Commercial Operations

14.8.2.10. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Preclinical / Clinical Operations

14.8.2.11. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Small Companies

14.8.2.12. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Mid-sized   Companies

14.8.2.13. Microbial Contract Biomanufacturing Market in Europe, 2020-2030:Share of Large / Very Large Companies

 

14.8.3.  MicrobialContract Biomanufacturing Market in Asia Pacific, 2020-2030

14.8.3.1. Microbial Contract Biomanufacturing Marketin Asia Pacific, 2020-2030: Share of Proteins

14.8.3.2. Microbial Contract Biomanufacturing Marketin Asia Pacific, 2020-2030: Share of Enzymes

14.8.3.3. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Growth Hormones

14.8.3.4. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Antibody- based Drugs

14.8.3.5. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Other Biologics

14.8.3.6. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Bacterial Cell-based Expression Systems

14.8.3.7. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Yeast Cell-basedExpression Systems

14.8.3.8. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Other Microbial Cell-based Expression Systems

14.8.3.9. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Commercial Operations

14.8.3.10. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Preclinical / Clinical Operations

14.8.3.11. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Small Companies

14.8.3.12. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Mid-sized Companies

14.8.3.13. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Large / Very Large Companies

 

14.8.4.  MicrobialContract Biomanufacturing Market in Middle East and North Africa, 2020-2030

14.8.4.1. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Proteins

14.8.4.2. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030:            Shareof Enzymes

14.8.4.3. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030:            Shareof Growth Hormones

14.8.4.4. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030:            Shareof Antibody-based Drugs

14.8.4.5. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030:            Shareof Other Biologics

14.8.4.6. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030:            Shareof Bacterial Cell-based Expression Systems

14.8.4.7. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Yeast Cell-based Expression Systems

14.8.4.8. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems

14.8.4.9. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Commercial Operations

14.8.4.10. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Preclinical / Clinical Operations

14.8.4.11. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030:          Share of Small Companies

14.8.4.12. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030:          Share ofMid-sized Companies

14.8.4.13. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030:          Share ofLarge / Very Large Companies

 

14.8.5.  MicrobialContract Biomanufacturing Market in Latin America, 2020-2030

 

15.        IMPACT OF COVID-19 PANDEMIC ON MICROBIALCONTRACT BIOMANUFACTURING MARKET

15.1.     ChapterOverview

15.2.     CurrentOptions and Recuperative Initiatives of Key Players

15.2.1.  KBIBiopharma

15.2.2.  Lonza

15.2.3.  PortonPharma Solutions

15.2.4.  WackerBiotech

15.2.5.  WuxiAppTec

15.3.    Impact on Microbial Contract Biomanufacturing Market Opportunity

15.4.    Recuperative Strategies for CMO Businesses

15.4.1. Strategies for Implementation in the Short / Mid Term

15.4.2. Strategies for Implementation in the Long Term

 

16.        SWOTANALYSIS

16.1.     ChapterOverview

16.2.     Strengths

16.3.     Weaknesses

16.4.     Opportunities

16.5.     Threats

16.6.     Comparisonof SWOT Factors

 

17.        CONCLUDINGREMARKS

17.1.     ChapterOverview

 

18.        INTERVIEWTRANSCRIPTS

18.1.     ChapterOverview

18.2.     MeteoricBiopharmaceuticals

18.2.1.  CompanySnapshot

18.2.2.  Interview Transcript:Gaurav Kaushik, Managing Director and Chief Executive Officer (Q4 2019)

 

18.3.     ListBiological Laboratories

18.3.1.  CompanySnapshot

18.3.2.  Interview Transcript:Debbie Pinkston, Vice President, Sales and Business Development (Q3 2019)

 

18.4.     OLON

18.4.1.  CompanySnapshot

18.4.2.  InterviewTranscript: Andrea Conforto, Sales and Marketing-Bioservices Director)

18.5.     LuinaBio

18.5.1.  CompanySnapshot

18.5.2.  InterviewTranscript: Max Rossetto, General Manager-Business Development

 

18.6.     WACKERBiotech

18.6.1.  CompanySnapshot

18.6.2.  InterviewTranscript: Rob van Dijk, Business Development Manager (Q4 2019)

 

19.        APPENDIX 1:TABULATED DATA

 

20.        APPENDIX 2:LIST OF COMPANIES AND ORGANISTIONS

 

 

Contact Details

GauravChaudhary

+1(415) 800 3415

gaurav.chaudhary@rootsanalysis.com